| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11571478 | DUSA | Methods for photodynamic therapy |
Jan, 2038
(14 years from now) | |
| US11077192 | DUSA | Methods for photodynamic therapy |
Jan, 2038
(14 years from now) | |
| US10357567 | DUSA | Methods for photodynamic therapy |
Jan, 2038
(14 years from now) | |
| US11135293 | DUSA | Methods for photodynamic therapy |
Jan, 2038
(14 years from now) | |
| US11690914 | DUSA | Methods for photodynamic therapy |
Jan, 2038
(14 years from now) | |
Levulan is owned by Dusa.
Levulan contains Aminolevulinic Acid Hydrochloride.
Levulan has a total of 5 drug patents out of which 0 drug patents have expired.
Levulan was authorised for market use on 03 December, 1999.
Levulan is available in solution;topical dosage forms.
Levulan can be used as treatment of actinic keratoses of upper extremities by photodynamic therapy.
The generics of Levulan are possible to be released after 12 January, 2038.
Drugs and Companies using AMINOLEVULINIC ACID HYDROCHLORIDE ingredient
Market Authorisation Date: 03 December, 1999
Treatment: Treatment of actinic keratoses of upper extremities by photodynamic therapy
Dosage: SOLUTION;TOPICAL
LEVULAN family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic